Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspsolution for infusions
    Composition:
    100 ml:
    Active substance: fluconazole - 0.2 g.
    Excipients: sodium chloride - 0.9 g, water for injection - up to 100 ml.

    Description:: transparent colorless or slightly yellowish tinge
    Pharmacotherapeutic group:Antifungal agent.
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:
    Fluconazole is a representative of the class of three azole antifungal agents. Has a highly specific effect, inhibiting the activity of enzymes of fungi, dependent on cytochrome P450. Blocking the conversion of lanosterol of fungal cells to ergosterol; increases the permeability of the cell membrane, disrupts cell growth.
    Fluconazole, being highly selective for cytochrome P450 fungi, practically does not inhibit these enzymes in the human body (in comparison with itraconazole, clotrimazole, econazole and ketoconazole, to a lesser extent suppresses the oxidative processes dependent on cytochrome P450 in human liver microsomes). Does not have anti-androgenic activity. It is active in opportunistic mycoses, including those caused by Candida spp, (including generalized forms of candidiasis on the background of immunodepression), Cryptococcus neoformans and Coccidioides immitis (including intracranial infections), Microsporum spp. and Trichophyton spp., with endemic mycoses caused by Blastomyces dermatidis, Histoplasma capsulatum (including immunosuppressed Gressy and).

    Pharmacokinetics:
    After intravenous administration, the fl ucopolase well penetrates into the tissues and body fluids.
    Distribution
    The concentration in the plasma is in direct proportion to the dose. The concentration of the active substance in breast milk, articular fluid, saliva, sputum and peritoneal fluid is similar to that in plasma. In the fluid, epidermis and stratum corneum (selective accumulation), concentrations exceeding serum levels are achieved. It penetrates well into the cerebrospinal fluid, with fungal meningitis, the concentration in the cerebrospinal fluid is about 85% of that in the plasma. About 90% of the equilibrium concentration of the fl ∞-a plasma (Css) is reached by 4-5 days. The introduction of a "shock" dose (on the first day), which is 2 times higher than the usual daily dose, allows one to achieve a concentration corresponding to 90% Css, to 2 dosho.
    Apparent volume of distribution (W) approaches the total content of fluid in the body. The connection with plasma proteins is low - 11-12%.
    Metabolism and excretion
    The half-life (T1 / 2) is 30 hours. It is an inhibitor of the CYP2C9 isoenzyme in the liver. It is excreted mainly by the kidneys (80% - unchanged, 11% - in the form of metabolites). The clearance of fluconazole is proportional to the creatinine clearance. The pharmacokinetics of fluconazole significantly depends on the functional state of the kidneys,there is an inverse relationship between Tj / 2 and creatinine clearance (CC). After hemodialysis, within 3 hours the concentration of fluconazole in the plasma is reduced by 50%.
    The pharmacokinetics of fluconazole is similar for intravenous administration and ingestion, which allows one to easily switch from one type of reception to another.

    Indications:
    Cryptococcosis, including cryptococcal meningitis and other localization infections (eg, lung, rut), both in patients with normal immune response, and in patients with various forms of immunosuppression (including AIDS patients, organ transplantation); Supportive therapy for the prevention of recurrences of cryptococcosis in AIDS patients.
    Generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infection, such as peritoneal infections,
    endocardium, eye, bronchopulmonary system and urinary tract, including patients with malignant tumors in intensive care units, patients receiving cytotoxic or immunosuppressive agents, as well as in patients with other factors predisposing to the development of candidiasis.
    Prevention of cagedtosis in the presence of a high risk of generalized infection, for example in patients with severe or long-lasting neutropenia.
    Deep endemic mycoses (coccidiomycosis, histoplasmosis) in patients with chronic obstructive pulmonary disease
    Oropharyngeal candidiasis, esophageal and mucosal capsidosis in children.
    Contraindications:
    Hypersensitivity to the components of the drug (including other azole antifungal drugs); simultaneous reception of terfenadine (against the background of a constant intake of fluconazole at a dose of 400 mg / day or more), cisapride, pimozide, astemizole, quinidine; congenital or revealed elongation of the QT interval on the electrocardiogram, simultaneous reception of drugs prolonging the QT interval (angiarhythmics of IA and III classes); lactation period.

    Carefully:Liver failure, the appearance of rash against the background of fluconazole in patients with superficial fungal infection and invasive / systemic fungal infections, concurrent administration of terfenadine and fluconazole at a dose of less than 400 mg / day, potentially arrhythmogenic conditions in patients with multiple risk factors(organic heart diseases, electrolyte balance disorders, simultaneous reception of medications that cause arrhythmias), pregnancy.
    Pregnancy and lactation:
    Fluconazole should be avoided during pregnancy, except in cases of severe and potentially life-threatening fungal infections, when the expected benefit of fluconazole for the mother exceeds the possible risk to the fetus. Since the concentration of fluconazole in breast milk and in plasma is the same, apply the drug during lactation (during breastfeeding) - is contraindicated.

    Dosing and Administration:
    Intravenously drip at a speed of no more than 200 mg / h. The daily dose of fluconazole depends on the nature and severity of the fungal infection. When transferring from intravenous administration to taking pills and vice versa, there is no need to change the daily dose. Treatment can begin before the results of sowing and other laboratory
    research. However, therapy needs to be changed accordingly when the results of these studies become known.
    Adults
    When cryptococcal meningitis and krshpokkovyh infections of other locations on the first day, an average of 400 mg flukonavola, and then continue treatment at a dose of 200-400 mg once a day.The duration of treatment for cryptococcal infections depends on the clinical efficacy, confirmed by mycological examination; with cryptococcal meningitis, it usually lasts a minimum of 6-8 weeks.
    To prevent the recurrence of cryptococcal meningitis in AIDS patients after completion of the full course of primary treatment. Therapy with fluconazole at a dose of 200 mg / day can be continued for a very long period (transition to an oral form is possible).
    With candidemia, disseminated candidiasis and other invasive candidiasis infections, the average dose is 400 mg on the first day, then 200 mg per day. With insufficient clinical efficacy, the dose of fluconazole can be increased to 400 mg / day. The duration of therapy depends on clinical effectiveness.
    For the prevention of candidiasis in the presence of a high risk of generalized infection, for example in patients with severe or persistent neutropenia, the recommended dose is 400 mg once a day. Fluconazole prescribe a few days before the expected appearance of neutrons and after increasing the number of neutrophils more than 1000 / μl, treatment is continued for another 7 days.
    With deep endemic mycoses, it may be necessary to use the drug at a dose of 200-400 mg / day for 2 years. The duration of therapy is determined individually; it is 11 - 24 months with coccidioidomycosis, with histoplasmosis - 3-17 months (transition to an oral form is possible).
    Children
    In children, as with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. In children, the drug should not be used in a daily dose that would exceed that of adults, that is, not more than 400 mg per day. The drug is used daily 1 time per day. If it is necessary to carry out long-term therapy, it is possible to switch to the oral form of fluconazole.
    In cryptococcal meningitis and cryptococcal infections of other proofs, as well as generalized candidiasis in children, the recommended dose is 6-12 mg / kg / day, depending on the severity of the disease. Duration of therapy - for 10-12 weeks (before laboratory confirmation of the absence of pathogens in the cerebrospinal fluid).
    To prevent the recurrence of cryptococcal meningitis in children with AIDS, after the completion of the full course of primary treatment, fluconazole therapy at a dose of 6 mg / kg / day can be continued for a long time.
    With oropharyngeal candidiasis in children, the recommended dose is 6 mg / kg on the first day, then daily at 3 mg / kg / day, once. Duration of therapy - for at least 2 weeks.
    When candidiasis of the mucous membranes in children, the recommended dose of flavonazole is 3 mg / kg / day. On the first day, a shock dose of 6 mg / kg may be prescribed to achieve a more rapid equilibrium equilibrium concentration. The duration of therapy is at least 3 weeks.
    When Candidiasis of the esophagus in children, the fl ucopase is administered once in a daily dose of 3 mg / kg. On the first day, a shock dose of 6 mg / kg / day can be prescribed. Depending on the severity of the disease, the dose can be increased to 6-12 mg / kg / day. Duration of therapy
    at least 3 weeks and 2 weeks after the regression of the symptoms.
    For the prevention of fungal infections in children with reduced immunity, the risk of infection is associated with neutropenia, which develops as a result of cytotoxic chemotherapy or radiation therapy, the flipopalone is administered once in a daily dose of 3-12 mg / kg / day. The duration of therapy is until elimination of induced neutropenia.
    When the drug is used in children aged from the period of ivorocity up to 4 weeks
    it should be borne in mind that in newborns fluconazole output slowly.In the first 2 weeks of life, the drug is administered at the same dose (in mg / kg) as for older children, but at an interval of 72 hours. Children up to 4 weeks of age are given the same dose at intervals of 48 hours.
    Application in the elderly.
    In the absence of violations of the kidneys should follow the usual dosage regimen. Patients with renal impairment (creatinine clearance less than 50 mL / min) dosing regimen should be adjusted as indicated below.
    Use of the drug in patients with impaired renal function.
    At K K less than 50 ml / min, correction of the dosing regimen is required.
    Fluconazole is excreted mainly with urine in unchanged form. With a single administration, a dose change is not required. In patients with impaired renal function with repeated use of the drug, a shock dose of 50 mg to 400 mg should be initially administered, after which the daily dose (depending on the indications) is determined according to the following table.

    Creatinine clearance (ml / min)

    Percent recommended dose

    less than 50 (without dialysis)

    50%

    more than 50

    100%

    Patients permanently on dialysis

    100% after each dialysis session

    Fluconazole is administered intravenously drip at a rate of no more than 200 mg / hour.J 1 with the transfer of the patient from intravenous administration to taking the drug inside or vice versa, changes in the daily dose are not required. In children with impaired function of the nights, the daily dose of the drug should be reduced (in the same proportional relationship as in adults), in accordance with the degree of renal failure The preparation contains 0.9% solution of sodium chloride; in 100 ml of the drug contains but 15 mmoles of sodium and chlorine ions, therefore, in patients who need to limit the intake of sodium or liquid, it is necessary to take into account the rate of fluid administration.


    Side effects:
    Fluconazole, as a rule, is well tolerated.
    Depending on the frequency of occurrence, the following groups of side affects are distinguished: frequent - more than 1%, infrequent - 0, L%, rare - 0,01-0,1%, very rare - less than 0,01%.
    Allergic reactions, infrequent skin rash, rarely multi-form exudative erythema (including Stevens-Johnson syndrome), toxic epidermal pskroliz (Lyell's syndrome), ayafilaktoidnye reactions (including angioedema, edema of the face, urticaria, itching of the skin).
    From the side of the central nervous system: infrequently - headache, dizziness, rarely - convulsions.
    On the part of the digestive system: infrequently - nausea, diarrhea, flatulence, abdominal pain, taste change, vomiting, rarely - impaired liver function (jaundice, hyperbilirubipaemia, increased activity of alanine inotropase.
    aspartate aminotransferase and alkaline phosphatase, hepatitis, hepatocellular necrosis), including fatal cases,
    ('On the side of the hematopoiesis: rarely - leukopenia, thrombocytopenia, neutropenia, agranulocytosis.
    On the part of the cardiovascular system: rarely - an increase in the duration of the QT interval, very rarely - ventricular fibrillation / flutter.
    Other: rarely - a violation of kidney function, alopecia, hypercholesterolemia,
    hypertriglyceridemia, hypokalemia.

    Overdose:
    Symptoms: hallucinations, paranoid but conducting.
    Treatment: symptomatic: forced diuresis. Hemodialysis within 3 hours reduces the plasma concentration by approximately 50%.

    Interaction:
    Anticoagulants. Fluconazole increases the incidence of antimicrobial kumari in new anticoagulants (for example, warfarin) by an average of 12%, so careful monitoring of prothrombin time in patients receiving fluconazole and coumarin anticoagulants.
    Oral hypoglycemic drugs, derivatives of sulfopyramide (chlorpropamide, glybeplamid, glgtizid and tolbutamide). With their simultaneous administration with fluconazole, the half-life of oral hypoglycemic drugs, sulfonylurea derivatives, is prolonged, which can lead to the development of hypoglycemia. Periodically monitor the concentration of glucose in the blood and, if necessary, adjust the dose of hypoglycemic drugs.
    Hydrochlorothiazide increases the concentration of fluconazole in plasma by 40%, but the ego does not require a change in the dosage regimen of fluconazole in patients receiving diuretics at the same time.
    Fenitoia. The simultaneous administration of fluconazole and phenytoin is accompanied by an increase in the concentration of the latter in a clinically significant degree. Therefore, it is necessary to monitor the level of phenytoin and select its dose to provide therapeutic serum concentrations.
    Oral contraceptives. Multiple application of fluconazole (in the vines 50-200 mg) does not affect the effectiveness of combined oral contraceptives.
    Reef.Simultaneous application of fluconazole and rifampicin resulted in a 25% reduction in the AUC (area under the pharmacokinetic curve) and 20% of the duration of the fluconazole half-life period. With the simultaneous administration of rifampicin and fluconazole, it is necessary to increase the dose of fluconazole.
    Cyclosporine. When treating fluconazole, it is recommended to monitor the concentration of cyclosporine in the blood.
    Vorichoazol. When treating fluconazole, it is recommended to monitor the concentration of voriconazole in the blood, which requires monitoring of its concentration and dose adjustment. Azithromycin. When treating fluconazole, it is recommended to control the concentration of azithromycin in the blood, which requires monitoring of its concentration and dose adjustment. Theophilia. Fluconazole prolongs the half-life of theophylline and increases the risk of intoxication (it is necessary to correct its dose).
    Terfenadip. Simultaneous administration of fluconazole in doses of 400 mg / sug and more with terfenadine is contraindicated. Treatment with fluconazole in doses less than 400 mg / day in combination with terfenadine should be done under the close supervision of a physician. Tzgapride. With the simultaneous administration of fluconazole and cisapride, unwanted reactions from the heart, including paroxysms of ventricular tachycardia (torsade depointes).
    Rifabutin.The simultaneous use of fluconazole and rifabutin may lead to an increase in serum concentrations of the latter. With the simultaneous use of fluconazole and rifabutin, cases of uveitis are described. Patients receiving concurrently rifabutin and fluconazole, must be carefully observed.
    Tacrolimus. Fluconazole increases the concentration of tacrolimus, in connection with which, the risk of nephrosis increases.
    Zidovudine. In patients receiving a combination of fluconazole and urodin, an increase in the concentration of zidovudine is observed, which is caused by a decrease in the conversion of the latter into its main metabolite, so the side effects of zidovudine should be expected to increase.
    Midazolam. Fluconazole increases the concentration of midazolam, which increases the risk of developing psychomotor effects (most pronounced when fluconazole is administered orally than intravenously).

    Special instructions:
    Treatment should continue until the appearance of clinical and microbiological remission. Premature termination of treatment leads to relapse.
    Treatment can be started in the absence of seeding results or other laboratory tests, but if appropriate, appropriate correction of antifungal therapy is recommended.In the course of treatment, it is necessary to monitor blood counts, kidney and liver function.
    It is necessary to monitor the prothrombin index with simultaneous application with anticoagulants of the coumarin series. If there are violations of kidney and liver function, stop taking the drug.
    In rare cases, the use of fluconazoa was accompanied by toxic changes in the liver.
    In the case of hepatotoxic effects associated with fluconazole, their developmental dependence was not observed on the total daily dose, duration of therapy, sex, and age of the patient.
    The hepatotoxic effect of fluconazole was usually reversible; signs of it disappeared after discontinuation of therapy. If there are clinical signs of liver damage that may be associated with fluconazole, the drug should be discontinued.
    Patients with AIDS are more likely to develop severe skin reactions with many drugs. In those cases when the rash develops in patients with fungal infection, and it is regarded as definitely associated with fluconazole, the drug should be discontinued. When rashes occur in patients with systemic fungal infections,patients should be carefully monitored and with the appearance of bullous changes or m-form erythema fluconazole necessary cancel. It is recommended to monitor the concentration of cyclosporine in the blood in patients receiving fluconazole, since in patients with kidney transplantation the administration of fluconazole at a dose of 200 mg / day leads to a slow increase in the concentration of cyclosporin in the plasma. Caution should be exercised with simultaneous administration of fluconazole with rifabutin or other drugs metabolized by the pythochrome P450 system. Concurrent use with cisapride is contraindicated.
    Acceptance of some azoles, including fluconazole, may be accompanied by prolongation of the QT interval, therefore, the appointment of fluconazole to patients at risk of arrhythmias, especially severe patients with organic myocardial damage and conduction of the heart pathways, electrolyte imbalance and / or cardiothoracic supportive therapy, must be strictly justified and carried out under close medical supervision and monitoring the electrocardiogram. Patients receiving fluconazole and concurrently taking drugs with a narrow therapeutic range, metabolized with the help of isozymes CYP2C9 and CYP3A4, should be under medical supervision.

    Effect on the ability to drive transp. cf. and fur:
    Experience with flukonavol suggests that the deterioration in the ability to drive and drive machinery associated with the drug is unlikely.

    Form release / dosage:
    Solution for infusions 2 mg / ml.

    Packaging:
    For 50ml, 100 ml in bottles of light-protective or colorless glass with a capacity of 100 ml, hermetically sealed with stoppers rubber, crimped caps.
    For 100 ml in bottles of light-protective or colorless glass with a capacity of 100 ml, hermetically sealed with stoppers rubber, crimped caps.
    1 bottle or 1 bottle is placed in a pack of cardboard with instructions for use and suspension polymer or without suspension.
    35 bottles or bottles are placed in a box of corrugated cardboard with an equal number of instructions for use and suspension polymer or without suspension, for hospitals.
    Storage conditions:
    At a temperature of no higher than 30 ° C.
    Keep out of the reach of children.

    Shelf life:
    3 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000867
    Date of registration:14.10.2011
    The owner of the registration certificate:MS-VITA, LLC MS-VITA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia
    Information update date: & nbsp28.09.2015
    Illustrated instructions
      Instructions
      Up